skip to main content
Idioma:
Resultados 1 2 3 next page
Mostrar Somente
Refinado por: autor: Rosenstock, Julio remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial

SCHERNTHANER, Guntram ; GROSS, Jorge L ; ROSENSTOCK, Julio ; GUARISCO, Michael ; MIN FU ; YEE, Jacqueline ; KAWAGUCHI, Masato ; CANOVATCHEL, William ; MEININGER, Gary

Diabetes care, 2013-09, Vol.36 (9), p.2508-2515 [Periódico revisado por pares]

Alexandria, VA: American Diabetes Association

Texto completo disponível

Citações Citado por
2
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)

RIDDLE, Matthew C ; ARONSON, Ronnie ; HOME, Philip ; MARRE, Michel ; NIEMOELLER, Elisabeth ; MIOSSEC, Patrick ; LIN PING ; YE, Jenny ; ROSENSTOCK, Julio

Diabetes care, 2013-09, Vol.36 (9), p.2489-2496 [Periódico revisado por pares]

Alexandria, VA: American Diabetes Association

Texto completo disponível

Citações Citado por
3
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

ROSENSTOCK, Julio ; AGGARWAL, Naresh ; POLIDORI, David ; YUE ZHAO ; ARBIT, Deborah ; USISKIN, Keith ; CAPUANO, George ; CANOVATCHEL, William

Diabetes care, 2012-06, Vol.35 (6), p.1232-1238 [Periódico revisado por pares]

Alexandria, VA: American Diabetes Association

Texto completo disponível

Citações Citado por
4
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)

RIDDLE, Matthew C ; FORST, Thomas ; ARONSON, Ronnie ; SAUQUE-REYNA, Leobardo ; SOUHAMI, Elisabeth ; SILVESTRE, Louise ; LIN PING ; ROSENSTOCK, Julio

Diabetes care, 2013-09, Vol.36 (9), p.2497-2503 [Periódico revisado por pares]

Alexandria, VA: American Diabetes Association

Texto completo disponível

Citações Citado por
5
11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy
11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy

Rosenstock, Julio ; Banarer, Salomon ; Fonseca, Vivian A ; Inzucchi, Silvio E ; Sun, William ; Yao, Wenqing ; Hollis, Gregory ; Flores, Robert ; Levy, Richard ; Williams, William V ; Seckl, Jonathan R ; Huber, Reid

Diabetes care, 2010-07, Vol.33 (7), p.1516-1522 [Periódico revisado por pares]

United States: American Diabetes Association

Texto completo disponível

Citações Citado por
6
Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥52-week randomized, double-blind study
Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥52-week randomized, double-blind study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥52-week randomized, double-blind study

YKI-JÄRVINEN, Hannele ; ROSENSTOCK, Julio ; DURAN-GARCIA, Santiago ; PINNETTI, Sabine ; BHATTACHARYA, Sudipta ; THIEMANN, Sandra ; PATEL, Sanjay ; WOERLE, Hans-Juergen

Diabetes care, 2013-12, Vol.36 (12), p.3875-3881 [Periódico revisado por pares]

Alexandria, VA: American Diabetes Association

Texto completo disponível

Citações Citado por
7
Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets
Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets
Material Type:
Artigo 		Adicionar ao Meu Espaço

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets

DeVries, J Hans ; Bain, Stephen C ; Rodbard, Helena W ; Seufert, Jochen ; D'Alessio, David ; Thomsen, Anne B ; Zychma, Marcin ; Rosenstock, Julio

Diabetes care, 2012-07, Vol.35 (7), p.1446-1454 [Periódico revisado por pares]

United States: American Diabetes Association

Texto completo disponível

Citações Citado por
8
Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes
Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes

Riddle, Matthew ; Umpierrez, Guillermo ; DiGenio, Andres ; Zhou, Rong ; Rosenstock, Julio

Diabetes care, 2011-12, Vol.34 (12), p.2508-2514 [Periódico revisado por pares]

Alexandria, VA: American Diabetes Association

Texto completo disponível

Citações Citado por
9
Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

Rosenstock, Julio ; Klaff, Leslie J ; Schwartz, Sherwyn ; Northrup, Justin ; Holcombe, John H ; Wilhelm, Kenneth ; Trautmann, Michael

Diabetes care, 2010-06, Vol.33 (6), p.1173-1175 [Periódico revisado por pares]

Alexandria, VA: American Diabetes Association

Texto completo disponível

Citações Citado por
10
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
Material Type:
Artigo 		Adicionar ao Meu Espaço

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

Rosenstock, Julio ; Reusch, Jane ; Bush, Mark ; Yang, Fred ; Stewart, Murray

Diabetes care, 2009-10, Vol.32 (10), p.1880-1886 [Periódico revisado por pares]

Alexandria, VA: American Diabetes Association

Texto completo disponível

Citações Citado por
Resultados 1 2 3 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (25)

Data de Publicação 

De até
Refinar
  1. Antes de2010  (2)
  2. 2010Até2011  (5)
  3. 2012Até2014  (15)
  4. 2015Até2018  (4)
  5. Após 2018  (3)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.